Studies
Swipe or Scroll to see our currently enrolling studies.
Open Label Treatment for Depression
Adams Clinical sponsors an open-label study for those who are experiencing depression and want to participate in a clinical trial. For each 6 week treatment cycle, Adams Clinical monitors participants' responses to an FDA- approved antidepressant as part of the TRAIT-MDD-107 protocol.
1st Line Treatment for MDD
Adams Clinical is testing NMRA-335140 in individuals who are experiencing depression. NMRA-335140 is a Kappa Opioid Receptor (KOR) antagonist aimed at modulating dopamine in the brain and is being tested in the NMRA-335140-301 protocol.
2nd Line Adjunctive Treatment for MDD
Adams Clinical is testing BI 1569912 in individuals who are experiencing depression and have failed to respond to at least one antidepressant. BI 1569912 is an NMDA receptor inhibitor and is being tested in the 1447-005 protocol.
2nd-Line Adjunctive Treatment for Depression
Adams Clinical is testing ulotaront in individuals who are experiencing depression and have failed to respond to at least one antidepressant. Ulotaront is a TAAR1 agonist and is being tested in the 382-201-00001 protocol.
1st Line Treatment for MDD
Adams Clinical is testing BHV-7000 in individuals who are experiencing depression. BHV-7000 is a Kv7 activator aimed at slowing the rate at which potassium channels close in the brain. BHV-7000 is being tested in the BHV-7000-305 protocol.
Early Alzheimer’s Disease
Adams Clinical is testing BMS-986446 in individuals with Early Alzheimer’s Disease. BMS-986446 is a monoclonal antibody directed at the microtubule binding region of the tau protein to prevent reuptake into the cell. BMS-986446 is being tested in the CN008-0003 protocol.
-
‹
-
›